MCQ 21/12/58

()

1
1.
Doctors order sheet
2.

3.
Medication administration
record
4.
consent form
5..
2 5. aspiration
1. inspection
2. palpation
3. percussion
4. auscultation
5. aspiration
3 4. Neutrophil

1. Mast cell
2. Macrophage
3. Monocyte
4. Neutrophil
5. Eiosinophil
4 Ergotamine 4. ETV

1. LPV/r
2. EFV
3. NVP
4. ETV
5. IDV
5 5. 90% CI

1. 1 AUC
2. Cmax
3. AUC Cmax


4. 90% CI AUC
. Cmax ..
5. 90% CI

 1 AUC Cmax
6 pralidoxime 4.

Acetylcholinesterase
1.
2. Cholinergic receptor
3. Acetylcholinesterase
4. Acetylcholinesterase

5. (
)

7 2. Idiosyncrasies





1. Drug resistance
2. Idiosyncrasies
3. Refractoriness
4. Tachyphylaxis
5. Tolerance
8
9
1 . 2. direct non medical cost
0

1. direct medical cost
2. direct non medical cost
3. non medical cost
4. intangible cost
5. fixed cost
1
1
1 enz. dipole-dipole
2 H O ( H
1. ionic interaction bond)
2. covalent interaction
3. hydrophobic interaction
4. dipole-ionic interaction
5. dipole-dipole interaction
.

enz.

glutamate
1 13. Nicotinic acid 5 g NaOH
3 1 N 5 ml nicotinic
acid %w/w (MW of nicoticnic acid
 is 123)
1. 1.23 %w/w
2. 12.3 %w/w
3. 24.6 %w/w
4. 49.4 %w/w
5. 61.5 %w/w
1 4. USP
4 Method validation
System suitability
1. In house method
2. J. Pharm. Sci.
3.
4. USP
5.



1 phenol
5 270 nm
phenol 1 N NaOH
Product

1. ,

2. ,
270 nm

3. ,
270
nm
4. 3 O-
OH2+ ,
270 nm
3 O- OH2+
, 270 nm
1 3. resolution
6 HPLC
1. plate number
2. tailing factor
3. resolution
4. retention time
5 ...
1 4. Moringa oleifera
7

 1.
2. Centella asiataca
3. Alpinia galanga
4. Moringa oleifera
5. Senna siama
1 (crude extract) 2. 80%
8




1.
2. 80%
3.
4.
5.

1 1. Sugar coated
9 dosage form
1. Sugar coated
2. Chewable
3. Suspension
4. Mixture
5. Emulsion
2 NaH2PO4 0.08 N 2) 6.9
0 Na2HPO4 0.16 N pH
( pKa2 Na2HPO4
= 7.2)
1) 6.5
2) 6.9
3) 7.1
4) 7.5
5) 8
2 colliod 2. Flocculation
1 1. Aggregation
2. Flocculation
3. Deflocculation
2 capsule
2 1. weight variation,moisture,...
2. friability,hardness,disintrgrant,...
3. friability,disintegrant,...
4.
5.

2
3
2
4
2

5 (angina) [
]
1. (1ring

HN )
2. Amyl nitrite
3. ( Erythritol tetranitrate N
)
4. Nitroglycerine
5. ( 2ring N
)
2
MI BP 180/120 2
6 1. IV nicardipine 3. IV
nitroglycerin IV
1. IV nicardipine nitroglycerin
2. IV verapamil Onset 2
3. IV Nitroglycerine Nicardipine
4. IV furosemide
MI, acute
5. IV Hydralazine HF

2 PT PTCA with bere metal 4. ASA + clopidogrel

7 stent
ACC/AHA 2014
1. ASA
2. clopidogrel
3. ASA + dipyridamole
4. ASA + clopidogrel
5. clopidogrel + ticagrelor
2 EF = 35%
8 Enarapril , SL-nitrate




1. Diltiazem
2. Digoxin
3. Losartan
4. HCTz
5. Spironolactone
2
9
3
0


/

1. rhabdomyosis
atorvastatin
2. cyanide nitrate SL
3. metoprolol firstpass
metabolism
 4. Drug interaction
enalapril antiplatelet agent
5. hyperkalemia
K sparing enalapril
3

1 Glycoprotein IIb/IIIa inhibitors

1. Alteplase
2. Clopidogrel
3. Ticlopidine
4.
5. Streptokinase

3
2

1. case report
2. cohort study
3. quasi experimental research
4. randomized controlled trial
5. Systematic Review and Meta-
analysis
3


3

1.
2.
3.
4.
5.
3
4 Angina
3 Sublingual nitrate 5.
5 1. 1-2

2.
3. Jugular
vein
4.


5.

3 SL nitrate
6 1. Enteric coated tablets
2. Extended release tablets
3. compressed tablets
4. Effervescent tablets
 5. Chewable tablets

3 Case
7 56 168 cm
CC:
: 3
2 CHF 2
Lab:
AF with rapid ventricular...
EF 36 %
37.
ventricular rate
1. Atenolol
2. Flecanide
3. Carvedilol
4. Verapamil
5. Amiodarone
3
8
3
9
4 . Cardioversion 1. amiodarone .
0 . ( DM HF HTN-->> AF) structural heart disease
1.amiodarone (HTN,HF)
2. lidocaine
3. flecanide
4. propafenone
5. Dronedarone
4 Potassium channel 3.
1 reentry circuit Atrial AV node
Fibrilation
1.
SA node
2. Atria
3. AV node
4. Ventricle
5. effective refractory period
Atria
4 AF 1. amiodarone
2 warfarin warfarin


1. amiodarone
2. atenolol
3. digoxin
4. furoxetine ( choice )
5. verapamil
4 AF Prolong QT 1. Amiodarone
3 1. Amiodarone
 2. Digoxin
3. Metoprolol
4. Diltiazem
5. Propafenone
4 RR 5. 2.17
4

QT prolong

QT QT
prolong prolong
325 175 500
120 280 400
445 455 900
1.
2. 0.36
3. 0.45
4. 0.95
5. 2.17

4 1. active from
5

Warfarin
1. active from
2. S-isomer R-isomer
3. Coumarin
4
5. Warf Wisconsin Alumni
Research Foundation
4
5.
6

1.
2.
3.
4.
5.
4 Warfarin brown glass vit E 1. Antioxidant
7 vit E ?
1. Antioxidant
2. Presevative
 3. Suspending agent
4.

5. Flocculating agent
4 chelating agent 1. EDTA
8
1. EDTA
2. HPMC
3. Polyethylene glycol
4. povidone
5. polyvinyl alcohol
4 Case 62
9 DM type 2,
Hypertension, Ischemic stroke
MED : HCTZ, Enalapril,
Metformin, Glipizide, Aspirin
FH :
SH :
PE : BP 130/80 mmHg 65
kg 165 cm
Lab : Total cholesterol 295 mg/dl
Total triglyceride 150 mg/dl
HDL-C 40 mg/dl LDL-C
195 mg/dl


1. Simvastatin 20 mg
2. Atrovastatin 40 mg
3. Rosuvastatin 5 mg
4. Gemfibrozil 600 mg
5. Ezetimibe 10 mg
5
0
5 Parameter 2. Serum creatinine
1 ( )
1. liver transferase
2. Serum creatinine
3. Proteinuria
5
2 ( 49 ?)
1. furosemide
2. metformin
3. enarapril
4. aspirin (Choice

Calcium carbonate)
5. clarithomycin
5 LDL-C HMG-COA-Reductase
3
5
4
5
5
5
2. contempation
6
TTM
1. Precontemplation


2. Contemplation
3. Preparation
4. Action
5. Maintenence

5 lipid metabolism 1
7 hyperlipidemia
1
2
3
4
5
5 HMG-CoA reductase inhibitors
8 Total synthesis
1. Fluvastatin
2. Simvastatin
3. Cerivastatin
4. Rosuvastatin
5. Atorvastatin
5
9
6 /
Size 5. Zeta potentiometer
0 analysis
1. Seiving
2. Microscopy
3. Andreasen pipette
4. Coulter counter
5. Zeta potentiometer
6 32 165 cm 2.
1 (partly controlled)

2 (1 )
(
) 2
(1 )
(asthma) 5 2
(partly
2555 Ventolin 2 puff for asthma controlled)
prn... note:
 zyrtec 1 tab hs


2557 Budesonide 1 puff BID
( )

-
-
- /
-
2
- 2-3


61.

GINA guideline 2015
1. (well controlled)
(2.) (partly controlled)
3. (poorly controlled)
4. (uncontrolled)
5.
6 3.
2 !!


1.
2.
3.
4.
5. NSAIDs
6
3 budecort

1.
2. MDI spacer
3.
4.


5.

6 5
4

step up Therapy
1. Flixotide (Fluticasone propionate
. mcg) 1 puff tid
2. Berodual (Ipratropium bromide +
fenoterol)
3. Seretide (salmeterol 25 mcg
fluticasone propionate 125 mcg)
4. Symbicort (budesonide
 formoterol)
6 Long-acting bronchodilator 3. Formoterol
5 1. Budosenide
2. Fenosterol
3. Formoterol
4. Ipratropium
5. Salbutamol
6 salbutamol 3. beta-2 receptor
6 1. beta-1 receptor MIMs Thailand
2. beta-1 receptor
3. beta-2 receptor
4. M2 receptor
5. phosphodiesterase III, IV
6 salbutamol 5.Tremor
7 1. Bradycadia Medscape application
2. Constipation Salbutamol AE: Tremor
3. Dry mouth (20%), Nervousness in
4. Nausea/Vomiting children aged 2-6 years
5. Tremor (20%), Insomnia in children
aged 6-12 years receiving
4-12 mg q12hr (11%)

6 2 case control
8 study


1. case report study
2. case-control study
3. quisi-experimental study
4. randomized-control trial
5.
6 cholinergic side
9 effect (
)
7 4.
0 1.
2. (Hispidulin)
3.
4.
5. (Aminophylline)
Ref: www.manager.co.th
7 natural sweetener 5. Stevioside
1 1. 6-Gingerol
2. Andrographolide
3. Berberine
4. E...chinn
5. Stevioside
7 3. 1-3 micrometer
2

1. 100-300 nanometer
2. 400-900 nanometer
3. 1-3 micrometer
4. 4-9 micrometer
5. 10-30 micrometer
7 CASE 52 Wt 60 kg
3 Height 160 cm CC:

PMH: DM type
2, CKD MED: Ferrous sulfate, Insulin
LAB: Scr 2.8 Hb 9 Hct 27 73. CrCl
Cockcroft-Gault Equation
1. 19 ml/min
2. 21 ml/min
3. 22 ml/min
4. 24 ml/min
5. 26 ml/min

7

4 GINA guideline
( Ferrous fumarate 325
mg 1*2, Serum ferritin > 550,
TSAT > 33%, .
)1. Ferrous
fumarate 325mg 1*3
2. Ferrous sulfate 325mg 1*3
3. IV iron dextran
4. ESAs
5. Blood
7 3 ESRD 3.
5 Erythropoietin
stimulating agent (ESAs)


ESAs
1. iron status
EPO
2.

Hb > 13
3.


4.


5. Epo beta
Hb
alfa

7 ADR
4. ESAs : increase
6 1. Ferrous Fumarate : Angioedema cardiovascular and
2. Ferrous sulfate : Pure red cell thomboembolic events
aplasia Note :
3. IV Iron supplement: Influenza like ESAs : hypertension ,
syndrome Influenza like syndrome ,
4. ESAs : increase cardiovascular and Bone marrow suppress
thomboembolic events IV Iron : severe
5. ESAs : Hypotension anaphylactic reaction
Ferrous sulfate Ferrous
Fumarate:


7 Epoetin alfa Biosimilar 4. Pure red cell aplasia
7 drug ADR
?
1. Renal dysfunction
2. Dypnea
3. Anaphylactic reaction
4. Pure red cell aplasia
5.

7 Epo alfa 5. GI disorder ()

8 1. iron defeciency
2 neurodegenerative disorders
3. hyperlipidemia
4. hyperglycemia
5. GI disorder
7
1.
9
1.
2.


3.



4.
5. Ferric (Fe3+)

8 Epoetin alfa 5. Position of glycosilation

0 Epoetin beta
1. Degree of liosylation
2. Number of amino acid
 3. Amino acid sequence
4. Type of sugar in glycosilation
5. Position of glycosilation

8
1


1.
2.
3.
4.
5.
8 30
2 1.maceration
2.percolation
3.
4.decocsion
5.infusion
8 epoetin alfa prefill-
3 syringe
1.
2.
3. single dose
4.
5. ( )
8 epoetin alfa
4 prefill-syringe
1.
2.
3. 2-8
4.
5.

8
5


1. cost-minimization analysis
2. cost-effectiveness analysis
3. cost-benefit analysis
4. cost-utility analysis
5. cost-illness analysis
8
ADA 4. Glipizide
6 2015 FBG 260 mg/ HbA1C 9.6 , Scr Insulin glargine ADA
2.0
Insulin (basal)
Med : Glipizide 5 mg 2*2 po pc, A1C > 9%
 Pioglitazone 30 mg 1*1 po pc Metformin
1. Piogliazone 1*2 SCr 1.4
2. Metformin 850 mg 1*3 mg/dL
3.
Sitagliptin (max dose metformin 2550
4. Glipizide Insulin g/day
glargine )
5. Glipizide premix insulin
(NPH/RI)

8 () 5. statins
7



ADA 2015
1. ASA
2. ARBs
3. thiazide
4. BBs
5. statins
8
8 5
Premix insulin (70-30%)
20 unit 22 unit
HbA1c 6.9%

150 112 150

70

97 78 60 *
118 * * 128

105 * 47 *

113 90 55 115

145 * 63 *
126 103 * 134

 *

1. Premix insulin 30

2. Premix insulin

3. Premix insulin

4. Premix insulin

5. Premix insulin

8 1. ADR type A
9 Premix hypoglycemia
insuline

1. ADR type A
2. ADR type B
3. Additive drug interaction
4. Chemical drug interaction
5. Antagonist drug interaction
9
2.
0 1.
2.
3.
4.


5.
9
3. insulin lispro

1 Rapid acting insulin Rapid acting insulin
1. regular insulin Aspart, Lispro,
2. NPH insulin Glulisine onset 5-15
3. insulin lispro
4. insulin glargine
5. insulin detemir
9 PREECEDE- 5.
2 PROCEED Model Diabetics
type 2
1.
2.
3.
4.
5.
9
3
insulin glargine
isoelectric point (Pl)

insulin glargine
regular insulin ?

Chain A --- 5. Arg

Pl
Chain B
1. Val
2. Leu
3. Glu
4. Phe
5. Arg
9
4
9
5
9 Metacresol Premix 3. Preservative
6 insulin (suspension)
1. Buffering agent
2. Suspending agent
3. Preservative
4. Susquesting agent
5. Tonicity
9 case
7
HIV 2



T4 , T3 , free T4


1. Graves disease
2. Iodine deficiency
3. Hashimoto
4. Congenital cretinism
5. Post inflammatory thyroiditis
9
8
9 PTU
9 1. iodide
2.
3.
4. T3,T4
5. T3,
T4
1 (case ) PTU
0

0
1
0
1
1 PTU 2. Agranulocytosis
0


Serious ADR
2 1. Metabolic acidosis - Cardiovascular:Vasculitis
2. Agranulocytosis - Hematologic:
3. N/V Agranulocytosis (0.2% to
4. Seizure 0.5%), Aplastic anemia
5. Dermatitis - Hepatic:Hepatotoxicity,
Liver failure
- Renal:Nephritis
1
0
3
1
0
4
1 Stigmasterol X
0 T3, T4

5

1. Alkaloids 5.Terpinoids
2. Flavonoids triterpenes
3. Tanins
4. Saponins steroids
5. Terpinoids
triterpenoids
1 Carbimazole
0
6

1 y zero order
0 ([A])
7 x

1 Half life [A] 1 A
0 (


) Zero order
8 1. half life = [A]/2k

2. half life = 2[A]/k (slope= -k)
3. half life = 0.693/k
4.
5.

1
0
9
1
1 2555
0
1. <5 mg/dl
2. <5.5 mg/dl
3. <6 mg/dl
4. <6.5 mg/dl
5. <7 mg/dl

1

1
1 1.
2.
3.
4.
5.
1

1 30
2 4. decoction
1. maceration
2. percolation
3. reflux
4. decoction
 5. infusion
1 Allopurinol
1 1. Febuxostat
3 2. Benzpermarone
3. azathioprine
1
1 colchicine
4 1. metacolic acidosis
2. prolong QT
3. Agranulocytosis
4. Seizure
5. Dermatitis
1 colchicine 4.
1 1.
5 2.
3.
4.
5.
1 (Risk 4.
1 management) Root 4
6 cause analysis E
1.
Allopurinol SJS (Stevens

Johnson syndrome)
2. Diclofenac


Ibuprofen 400 mg 1x3
3.
Dicloxacillin
Diclofenac




4. Colchicine
1

5. .

1
1 Xanthine oxidase
7 1. Allopurinol 1. Allopurinol
 2. Colchicine

3. Sulfinpyrazone

4. Probenezid

5. benzbomarone

1
1
8
1 diclofenac 5. Shellac
1 omeprazole 20 mg (miracid)
9 omeprazole


polymer
1. Algitate
2. Chitosan
3. HPMC
4. Pectin
5. Shellac
1 Miracid
 2 Pellets
0
Pellets Binder
1. EC
2. MC
3. MCC
4. HPMC
5. Chitosan

MCQ 22/12/58
()

1 self determination right patient

1.
2.
3.
4.
5.

2

1. A
2. B

Morisky
3. C

4. D

 5. E


3 vancomycin (trough
concentration) PRSP

1. 5-10 mg/ml
2. 10-15 mg/ml
3. 15-20 mg/ml
4. 20-25 mg/ml
5. 25-40 mg/ml
4
CAP
Cef-3 IV 1g q 24 hr
+ Azithromycin IV q 24 hr

Lab : ..
PE : ....
SH : ....
All : Penicillin
: ....




1.
2.
3. Lab
4.
5. .
5 withdrawal symptoms 2. Diazepam



1. Levodopa
2. Diazepam
3. Fluoxetine
4. Trihexyphenidyl
5. ..
6 G 500 mg q 12 h Vd= 100 l ,
Cl= 120 ml/min Cl 60
ml/min
1. 250 mg q 24 h
2. 250 mg q 48 h
3. 500 mg q 24 h
4.500 mg q 48 h
5.1000 mg q 12 h
7


1.
 2.
3.
4.
5.

8 Fluconazole
1. ergosterol ...
2. lanosterol 14-alpha-demethylase
3. squalene epoxidase
4. ...
9 ceftriaxone
IM IV IV push
anaphylactic shock


1. E
2. F
3. G
4. H
5. I
10 A 500 mg %L.A. 380
95-110
380 mg A
.
1.

2.
3.
4.
5.

11 ( 1 ): Ca2+

neuropathy
( 2 ):
Ca2+
**
+
..
1. alkylating
agent

azirinium ion

 2. irinotecan

carbamate

3. ..
4.
metal cpx

Pt

5.
hydroxyurea

12 AZT 1. d4T
1. d4T (

)


ARV

13



1.
2.
3.
4.
5.
14 Capacity
1.
2.
3.
4. ...........................................
5.
15 MgSO4 250 mg 1 N HCl ..
assay Magnesium
sulfate
1. Acid-base titration
2. Redox titration
3. Complexometric titration
4. Precipitation titration
5. Gravimetric titration
16
0.05 M edetate
disodium 12.15 ml 0.05 M
edetate disodium blank
 0.15 ml magnesium sulfate

1. 73.12 mg
2. 72.22 mg
3. 74.02 mg
4. 72.82 mg
5. 73.42 mg
17
dragendraff's
1. bismuth
nitrogen

18 1
1.
2. ref compre

3. Rx19 1 62
4.
5.
19 o/w
emulsion
1. Bitter taste
2. Sour taste
3. Acrid taste
4. Oily taste
5. Salty taste
20
Amitriptyline 3.
musc
1. 1 receptor arinic receptor
2. calcium channel
3. muscarinic receptor
4. dopamine
21 Loratadine 10 mg 180 mg AV X =
98.8% K=2.4 S=10 T=100
1. 2.4
2. 14.2
3. 14.2
4. 24
5. 24
22 paracetamol 6 kg
10 mg/kg
23 Montelukast
24 100% ferrous sulfate 325
mg 1x3 Fe2+
 (MW FeSO4 = 151.9)
25

1. foil punch
2. fin seal wrap
3. end-fold wrap
4. strip pack
5. blister

26


1.
2.
3.
4. (child resistant)
5. tamper packeting
27 Case GI
2 : Glybenclamide
1. Prazosin Glybulide
2. Glybenclamide ADR GI Epigastric
3. Cephalexin fullness, Heartburn,
4. Amitriptyline Nausea
5. piren . Ref: Micromedex
28

1.
2.
3. NSAIDs
4.
5. T^T
29
Proton Pump 2. Hypogastrinemia
Inhibitors
1. Hip fracture
2. Hypogastrinemia
3. Vitamin B12 deficiency
4. Increase risk of Bacterial infection
5. Acute interstitial nephritis
30
GI motility D2 receptor
Acetylcholine esterase inhibitors
1. Misoprostol
 2. Domperidone
3. Cisapride
4. Mosapride
5. Itopride
31 systemic antacid
1. Aluminium hydroxide
2. Magnesium hydroxide
3. Magnesium sulfate
4. Calcium carbonate
5. Sodium bicarbonate
32 antacid 1 4 7
1 15 fl.oz

33 glutathione


1. omeprazole
2. ranitidine
3. antacid
4. misoprostol
5. cisapride
34 .. 2556

1.
2.
3.
4.
5.
35 4. Suspensions
1. Solutions
2. Emulsions
3. Gels
4. Suspensions
5. ..
36
2.
(
) "
1. "" "
2. ""
3.
4.
5. "
"
37

1.
 2.
3.
4.
5.
38

1. mefenamic acid
2.
3. NSAIDs
4. secondary
dysmenorrhea
5.
39 mefenamic acid
cyclooxygenase
40 2. Ibuprofen
1. Aspirin medscape
2. Ibuprofen
3. Mefenamic acid American
4. Naproxen academy of pediatrics
5. Piroxicam committee states that
drug is compatible with
nursing



41

42 ADR type A NSAIDs 5. tinnitus

1. dyspepsia ()
2. hypernatremia
3. nephrotoxic
4. prolong bleeding
5. tinnitus
43
naproxen IgE-Mediated

1. Diclofenac
2. Aspirin
3. Ibuprofen
4. Piroxicam
5. Indometacin
44 NSAIDs
1. (
)
2.
3.
 4.

5.


45 Naproxen

1. Ethylcellulose (EC)
2. Methylcellulose (MC)
3. hydroxypropylcellulose (HPC)
4. Hydroxy propyl methyl cellulose (HPMC)
5. Hydroxypropyl methylcellulose sodium
acetate

46
47 NSAID


1. asa
48 Thai herbal
pharmacopoeia iron (III) sulfate
deep blue

1. Terpenoid
2. Anthraquinone
3. Alkaloid
4. Flavonoid
5. Coumarin
49 CC: 6
HPI: 4 38c



1. DTwP + HBV
2. DTwP + OPV + HBV
3. OPV + MMR
4. MMR
5. OPV + HBV
50


1. IPV
2.
3.
4.
51 Vaccine
2. Pertussis
1. Tetanus
2. Pertussis
 3. Polio
4. Diphtheria
5. MMR

52

1. PEG
2. IL-2
3. TGF-1
4. TXA
5. PGF-
53 dTWP ADR dTAP < 7
54 Ampicillin

1. Efflovescence
2. Deliquescence
3. Hygroscopic

55


1.
2.
3.
4
()......
5. : polymeric solution
polymeric dis..()
56
57 HBV 4 5
1.
2. 2

3.


4. HBv
5.


: micromedex
contraindication. severe
allergic reaction after
and previous dose of
any hepatitis B
containing vaccine,
including yeast
58 2556 5.

6-12
1.
2.
3.
4.
5.
59
60 Vaccine pyrogen test
1. OPV
2. BCG
3. TT
4. DTP
5. MMR
61 69 75 kg 2.
155 cm T-
prednisolone 10 mg/day score



-2.5
BMD T-score -
2.3
(severe

osteoporosis)
1. -2.5
2. (osteopenia)
3. (osteoporosis) (osteoporosis)
4. (severe -2.5 -1
osteoporosis)
5. (osteopenia)
-1

62

1. 69 ( 65 )
2.
3. 75 kg (
72 kg)
4. prednisolone
5.
63

800 mg/day
1. calcium carbonate 800 mg 11 po pc
2. calcium carbonate 1000 mg 12 po pc
3. calcium carbonate 1000 mg 21 po pc
 4. calcium carbonate 1000 mg 13 po pc
5. calcium carbonate 1500 mg 13 po pc
64
Alendronate 70
mg + Vit D

Alendronate
1.
2. 10 - 15
3.

4.
5.

65 Alendronate 4.
..
1. . activation RANKL Osteoclast
2. OPG
3. G-CSF
4. . Osteoclast
5. ...
66 Alendronate
1. Thromboembolism
2. Cardiovascular
3. Hypotension
4. Hypocalcemia
67
Bisphosphanates ( 1 )

Bisphosphanates ( 2 )
1.
2.

3.
4.
5.
68 alendronate . 2. meta analysis of
randomized control trial



1. Randomized control trial
2. meta analysis of randomized control trial
3. economic evaluation ( )
4. case control case series study
5.
69
70 2.

 1. phytoestrogen
2. ref:
3.
4.
5. ,
.
71 Prednisolone 2. hardness

1. disintegration
2. hardness
3. dissolution
4. friability
5. content uniformity
72 prednisolone corticosteroid 3


(first-order
reaction) shelf-life (t90)
1. t90 = 2A/K
2. t90 = 2/AK
3. t90 = 0.105/K
4. t90 = 693/K
5. t90 = K/693 ()
73 3 3. Acute Otitis Media
Med: Paracetamol 125 mg/5 ml
2

15 kg. 38.8

1. Acute Pharyngotonsiltis
2. Sinustitis
3. Acute Otitis Media
4. Allergic Rhinitis
5.

74 Case ( 3
)

1. S. pneumoniae
2. S. aureus
3.
4. paracetamol induced ototoxicity
5. fungal infection
75

1.
2. paracetamol
3.
NSAIDs
 4. Acute febrile seizure
5.
76

( 15 kg)
1. Amoxicillin 500 mg 11 PO PC q 8 hr x
10 #30
2. Amoxicillin 250 mg/5 ml (1 60
ml) 10 ml q 8 hr x 10 # 5
3. Amoxicillin 125 mg/5 ml (1 60
ml) 5 ml q 8 hr x 10 # 8
4. Amoxicillin/Clavulonate 250 mg/ml 2 ml
q 8 hr x 10
5. Clindamycin 150 mg 11 PO PC q 12 hr
#20
77
amoxicillin
1. Cloxacillin
2. Benzathine penicillin
3. Ticarcillin
4. Benzylpenicillin
5. Ampicilli
78 Clindamycin
1. Anaerobic infection
2. MLS-type B resistance
3. Acne vulgaris
4. Ribosomal translocation
5. Chlolethiasis
79 Amoxycilin
1. transpeptidation
2. tranglycosylation
3. N-acetylmuramic acid
4. D-alanyl -D-alanine
5. recycling bactoprenol carrier
protein
80




1. Randomized control trial
2. Case crossover study
3. Case control study
4. Descriptive study
5. Economic evaluation study

81 1. Grisenofovin
 1. Grisenofovin (
2. Amoxicillin )
3. Tetracycline
4. Erythromycin
5. Penicillin
( )
82
1. Penicilin
2. Cephalosporin
3.
4. Carbapenem
5.
83 Paracetamol 4. capping
1. sticking
2. chipping
3. laminating
4. capping
5. filming
84 BCG
5. bladder cancer
1. multiple sclerosis BCG is a vaccine used
2. psoriasis to prevent tuberculosis
3. SLE (TB), but its also an
4. leprosy effective treatment for
5. bladder cancer some non-invasive
bladder cancers. Its
given directly into the
bladder (intravesical).

:
http://www.macmillan.or
g.uk/Cancerinformation/
Cancertypes/Bladder/Tr
eatingearly/BCGtreatm
ent.aspx

85 Hgb 8, Hct 25, Total bilirubin 0.1, Direct 2. Iron deficiency

bilirubin 0.8, MCV 65
Anisocytosis +1, Hook worm,

Red blood cell morphology : Hypochromic 3+,
Microcytic 3+
Anemia
1. Megaloblastic
2. Iron deficiency
3. Hemolysis
86
1. Hct 25, Total bilirubin 0.1, Direct bilirubin
0.8
2. Hct 25, Hgb 8, RBC
3. Hct 25, Total bilirubin 0.1, Direct bilirubin
0.8, MCV 65
4. Hct 25, Hypochromic 3+, Microcytic 3+
5. Hct 25, Hook worm, Anisocytosis +1
87 elemental Fe 4
200
ferrous fumarate
1. Ferrous sulfate 200 mg 1x3 ac elemental 33%
2. Ferrous sulfate 300 mg 1x3 ac 600x0.33 = 198
3. Ferrous gluconate 250 mg 2x3 ac
4. Ferrous fumarate 200 mg 1x3 ac
5. Ferrous fumarate 200 mg 2x3 ac
88





1.

2.

3. enteric
coated
4.

5.
89 2. Mitochondria
1. 1. Impaired respiratory dysfunction
2. 2. Mitochondria dysfunction
3. 3. Impaired renal function
4. 4. Cell dystrophy
. 5. Hepatocyte atrophy
90

1.
2.
3.
4.
5.
91 red blood cell macrocytic 5. folic acid

macrocytic
1. iron folic acid
2. calcium vitamin B12
 3. vitamin B2
4. vitamin B6
5. folic acid
92 Odd ratio
stroke


anemia
sample 1268 2.48%
Anemia 2417 1.58%
1. 0.17
2 . 0.63
3. 0.64
4. 1.57
5. 1.59
93 FeSO4

1. Acid-base titration
2. Redox titration
3. Precipitation titration
4. Potentiation titration
5. Complexation titration
94 2.
.. 2556
1.

2.
3.
4.
5.
95 Ferrous sulfate Uncoated tablets


96 95
(oxidation)
2. Blister
1.
2. Blister

3.
4. Strip foil
5.
97 97-108
32

5
28


8


1. Acute pyelonephritis
2. Gonorrhea
3. Acute uncomplicated cystitis
4. Syphilis
5. Chancroid
98 ( )
1. cotrimazole 100 mg bid 7
2. cotrimazole 100 mg2 tab bid 7

3. tinidazole 500 mg 4
4. tinidazole 500 mg 4
5. fluconazole 150 mg single dose
99
10 Phenazopyridium
0
10
1
10
2
10
3
10
4
10 -lactam ring -
5 lactamase

1.
2.
3. R2


steric
steric
4.
5. -OCH3

5.
10
2.
6 1.
2.
3. ()
 4.
5.
10
7
10 case 35
8


25 15 2-
3

1.
2. 35
3.
4. 25
5.
15
10

9 1. 7 mg/24 hr
2. 14 mg/24 hr
3. 21 mg/24 hr
4. 21 mg /24 hr
5. 7 mg 21 mg /24 hr
11
0
1.

2.

3. 4-5
4.
5.
11 nicotinic 5. varenicline
1 receptor
1. bupropion
2. clonidine
3. nortriptyline
4. topiramate
5. varenicline
11
2
11
Nicotine 2. Down regulation
3 Nicotine nicotinic receptor


1. Desensitization nicotinic receptor
 2. Down regulation nicotinic receptor
3. Idiosyncracy
4. Receptor upregulation
5. nicotine
11
4
11
5
11
6 2. Contemplation
6
6
stages of change

Transtheoretical Model
1. Precontemplation (
2. Contemplation Precontemplation
3. Preparation
4. Action Preparation
5. Maintenance
1 )
11 3
7
( )
1-5

20-80





:


20


5-15

5-35

4


7
3









11
8

Nicotine
11 Nicotin
9
1. -79
2. 247
3. molecular weight Nicotin = 162.23
4. Log K (w/o) 1.17
5. nicotin
10 mg/day

12
2.
0 1. 100%
2.

3.


2
4.
5.